Cargando…

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

BACKGROUND: Masitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patients with inoperable, chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516046/ https://www.ncbi.nlm.nih.gov/pubmed/25858497 http://dx.doi.org/10.1093/annonc/mdv133

Ejemplares similares

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity
por: Menendez, Cintia A., et al.
Publicado: (2023)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux, Jean-Marie, et al.
Publicado: (2014)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling
por: Julka, P K, et al.
Publicado: (2008)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
por: KATHAWALA, RISHIL J., et al.
Publicado: (2014)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021)

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
por: Drayman, Nir, et al.
Publicado: (2021)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mn6o1trgtoo3tr1v4db070cesv